Human immunodeficiency virus pathogenesis: Insights from studies of lymphoid cells and tissues

Clinical Infectious Diseases

Volumn 33, Issue 6, 2001, Pages 873-884

  Kilby, J M ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 2;

ARTICLE; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE DEPLETION; LYMPHOCYTOPOIESIS; LYMPHOID CELL; LYMPHOID TISSUE; PATHOGENESIS; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; SEROCONVERSION; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; HIV; HIV INFECTIONS; HUMANS; LYMPHOID TISSUE; MODELS, BIOLOGICAL; VIREMIA;

EID: 0035885056     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/322647     Document Type: Article

References (133)

1. HIV viral load markers in clinical practice
2. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
3. Decay characteristics of HIV-1-infected compartments during combination therapy
4. Acute AIDS retrovirus infection: Definition of a clinical illness associated with seroconversion
5. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immunodeficiency syndrome
6. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection
7. Parotid manifestations of HIV infection
8. Lymphoepithelial cysts of salivary glands: An immunohistochemical study of HIV-related and HIV-unrelated lesions
9. The Walter Reed staging classification for HTLV-III/LAB infection
10. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease
11. Prevalence and clinical significance of splenomegaly in asymptomatic HIV-1-infected adults. Swiss HIV Cohort Study
12. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques
13. + T cells
14. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection
15. + cells is mediated by the chemokine receptor CC-CKR-5
16. Identification of a major co-receptor for primary isolates of HIV-1
17. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
18. Acute human immunodeficiency virus type 1 infection
19. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure
20. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression
21. Macrophage-tropic variants initiate HIV-1 infection after sexual, parenteral, and vertical transmission
22. Genetic characterization of HIV-1 in blood and genital secretions: Evidence for viral compartmentalization and selection during sexual transmission
23. Follicular dendritic cells and virus-like particles in AIDS-related lymphadenopathy
24. + T cells
25. + T-helper cells
26. Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: Implications for HIV primary infection
27. Replication of HIV-1 in dendritic cell-derived syncytia at the mucosal surface of the adenoid
28. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells
29. Dendritic cells and the control of immunity
30. Understanding dendritic cells and T-lymphocyte traffic through the analysis of chemokine receptor expression
31. The immunopathogenesis of human immunodeficiency virus infection
32. HIV-1 seroconversion in patients with and without genital ulcer disease
33. + T cell demographics and dynamics in lymphatic tissues
34. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS
35. Macrophages as a source of HIV during opportunistic infections
36. + T cell depletion and viral replication in SIV infection
37. Selective depletion of rectal lamina propria rather than lymphoid aggregate CD4 lymphocytes in HIV infection
38. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression
39. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals
40. Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection
41. Infection of human tonsil histocultures: A model for HIV pathogenesis
42. + T cell depletion in HIV-1-infected human lymphoid tissue
43. Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo
44. CCR5 and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue
45. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
46. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
47. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
48. Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus-infected subjects in the absence or presence of effective therapy
49. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
50. Simian immunodeficiency virus burden in tissues and cellular compartments during clinical latency and AIDS
51. Multiple modes of cellular activation and virus transmission in HIV infection: A role for chronically and latently infected cells in sustaining viral replication
52. + T-cell responses associated with control of viremia
53. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection
54. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death
55. Quantitative image analysis of HIV-1 infection in lymphoid tissue
56. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR
57. Rapid accumulation of HIV in lymphatic tissue reservoirs during acute and early HIV infection: Implications for timing of antiretroviral therapy
58. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA
59. Residual HIV-1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/mL
60. Monitoring responses to antiretroviral treatment in HIV-1-infected patients by serial lymph node aspiration
61. Virus burden in lymph nodes and blood of subjects with primary HIV-1 infection on bitherapy
62. Correlation of virus load in plasma and lymph node tissue in human immunodeficiency infection
63. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection
64. Evolutionary pattern of HIV replication and distribution in lymph nodes following primary infection: Implications for antiviral therapy
65. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
66. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy
67. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged depression of plasma viremia
68. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
69. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy
70. The effect of commencing combination antiretroviral therapy soon after HIV-1 infection on viral replication and antiviral immune responses
71. Chemokines and cell migration in secondary lymphoid organs
72. Increase in CD4 lymphocyte counts after splenectomy in HIV-infected patients
73. Effect of splenectomy on T lymphocyte subsets in patients infected with HIV
74. Effect of splenectomy on T-cell subsets and plasma HIV viral titers in HIV-infected patients
75. Effect of splenectomy on slowing HIV disease progression
76. Turnover of naive and memory phenotype T cells
77. Lifespans of naive, memory, and effector lymphocytes
78. Mature murine B and T cells transferred to SCID mice can survive indefinitely and many maintain a virgin phenotype
79. + T-cell regeneration in HIV-infected adults
80. Analysis of the human thymic pervascular space during aging
81. + T-lymphocyte regeneration after intensive chemotherapy
82. High prevalence of thymic tissue in adults with HIV-1 infection
83. Analysis of the adult thymus reconstitution of T lymphocytes in HIV-1 infection
84. + T cell turnover
85. + T cells from HIV- discordant monozygotic twins
86. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans
87. + T-cell renewal in early HIV-1 infection: Effect of highly active antiretroviral therapy
88. + T lymphocytes in HIV-1 infection as measured by Ki-67 antigen
89. Rapid turnover of T lymphocytes in SIV-infected Rhesus macaques
90. + T lymphocyte turnover in SIV-infected macaques
91. T-cell division in HIV-1 infection is mainly due to immune activation: A longitudinal analysis in patients before and during HAART
92. Changes in thymic function with age and during the treatment of HIV infection
93. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy
94. + T cell homeostasis and function in advanced HIV disease
95. Functional T cell reconstitution and HIV-1-specific cell-mediated immunity during HAART
96. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315
97. Treatment of HIV infection with saquinavir, zidovudine, and zalcitabine
98. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues
99. TNF system levels in HIV-infected patients during HAART: Persistent TNF activation associated with virologic and immunologic treatment failure
100. In vivo analysis of Fas/Fas L interactions in HIV-infected patients
101. Diminished spontaneous apoptosis in lymphocytes from HIV-infected long-term non-progressors
102. Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection
103. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: The Swiss HIV Cohort Study
104. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infected adults treated with combination antiretroviral therapy
105. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy
106. Declining morbidity and mortality, among patients with advanced human immunodeficiency virus infection
107. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
108. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
109. Peptide-specific T cell response to Mycobacterium tuberculosis: Clinical spectrum, compartmentalization and effect of chemotherapy
110. + lymphocyte subpopulation in tuberculous pleuritis
111. Sequestration of T lymphocytes to body fluids in tuberculosis: Reversal of anergy following chemotherapy
112. Focal mycobacterial lymphadenitis following initiation of protease inhibitor therapy in patients with advanced HIV-1 disease
113. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy
114. Systemic inflammatory reaction after starting HAART in AIDS patients treated for extrapulmonary: Treatment with corticosteroids
115. Mycobacterial lymphadenitis associated with the initiation of combination antiretroviral therapy
116. Miliary tuberculosis with paradoxical expansion of intracranial tuberculomas complicating HIV infection in a patient receiving HAART
117. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and CMV retinitis
118. Immune recovery vitreitis associated with inactive cytomegalovirus retinitis: A new syndrome
119. + T-cell repopulation of lymphoid tissues after treatment of HIV-1 infection
120. In vivo estimates of division and death rates of human T lymphocytes
121. + repertorie during antiviral therapy
122. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies
123. Factors influencing T-cell turnover in HIV-1-seropositive patients
124. T-cell progenitor function during progressive HIV-1 infection and after antiretroviral therapy
125. Effect of HIV on thymic function before and after antiretroviral therapy
126. Immune repopulation after HAART in previously untreated HIV-1-infected children
127. Thymic size and lymphocyte restoration in patients with HIV infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy
128. + T cells in HIV-1-infected patients receiving highly active antiretroviral therapy
129. HIV-1 and T cell dynamics after interruption of HAART in patients with a history of sustained viral suppression
130. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy
131. Structured treatment interruptions to control HIV-1 infection
132. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
133. Immune control of HIV-1 following early treatment of acute infection